Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Investors in Iovance Biotherapeutics Inc (Symbol: IOVA) saw new options begin trading this week, for the September 19th expiration. One of the key data points that goes into the price an option ...

UBS has recently initiated Iovance Biotherapeutics Inc (IOVA) stock to Buy rating, as announced on October 24, 2024, according to Finviz. Earlier, on July 29, 2024, Piper Sandler had reduced the stock ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

Wells Fargo analyst Yanan Zhu maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report) yesterday. The company’s shares closed yesterday at $5.91. Discover outperforming ...

UBS has recently initiated Iovance Biotherapeutics Inc (IOVA) stock to Buy rating, as announced on October 24, 2024, according to Finviz. Earlier, on July 29, 2024, Piper Sandler had reduced the stock ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report) today. The company’s shares closed yesterday at $5.78. Discover ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Iovance Biotherapeutics (IOVA – Research Report) and Vir Biotechnology (VIR – Research Report ...